Hayes J R, Callaghan S, Grant A P
Diabete Metab. 1979 Sep;5(3):207-11.
Glibenclamide has been shown to stimulate an insulin releasing factor in the duodenum. The possibility that this effect is of importance in its hypoglycaemic action was investigated by studying the effect of galactose on insulin release before and after treatment with glibenclamide; galactose stimulates insulin release when given orally but has no effect when given parenterally; thus its ability to release insulin appears to reside in an action on a gut factor. Measurements of plasma glucose, insulin and glucagon were made on twelve maturity onset diabetic patients following an oral glucose tolerance test and an oral galactose tolerance test before and after one week of treatment with glibenclamide. Glibenclamide significantly reduced the blood glucose levels. Both basal insulin and basal glucagon levels were unchanged. The insulin response to oral glucose was enhanced. Glucagon levels before treatment did not suppression of glucagon levels. Galactose stimulated insulin release but insulin levels before and after treatment were identical. An effect of glibenclamide on gut insulin releasing activity was not demonstrated but the galactose tolerance test provides a useful technique by which to examine the enteroinsular axis.
格列本脲已被证明可刺激十二指肠中的胰岛素释放因子。通过研究半乳糖在格列本脲治疗前后对胰岛素释放的影响，来探讨这种作用在其降血糖作用中是否重要；半乳糖口服时可刺激胰岛素释放，但胃肠外给药时则无作用；因此，其释放胰岛素的能力似乎取决于对肠道因子的作用。在12名成年发病型糖尿病患者口服葡萄糖耐量试验和口服半乳糖耐量试验前后，在接受格列本脲治疗一周后，对其血浆葡萄糖、胰岛素和胰高血糖素进行了测量。格列本脲显著降低了血糖水平。基础胰岛素和基础胰高血糖素水平均未改变。对口服葡萄糖的胰岛素反应增强。治疗前的胰高血糖素水平并未抑制胰高血糖素水平。半乳糖刺激胰岛素释放，但治疗前后的胰岛素水平相同。未证明格列本脲对肠道胰岛素释放活性有影响，但半乳糖耐量试验提供了一种有用的技术，可用于检查肠胰岛轴。
